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Abstract
Recent data support the theory of the involvement of IL-17 in the pathogenesis of several
chronic inflammatory skin diseases (psoriasis, atopic dermatitis, acne, hidradenitis
suppurativa) and autoimmune skin diseases (alopecia areata, vitiligo, bullous diseases).
Even if the role of IL-17 in inflammatory and autoimmune diseases has been reported
extensively, its role in tumor is still controversial. Some reports show that Th17 cells
eradicate tumors, while others reveal that they promote the initiation and early growth of
tumors. Herein, we review the role of IL-17 in the involvement of some common
dermatologic diseases: psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, vitiligo,
melanoma, and nonmelanoma skin cancers.
Introduction
IL-17 is a cytokine whose family consists of six members,
from IL-17A to IL-17F, even if the term IL-17 usually refers to
IL-17A.1 All the family members share some activities: IL-17A,
IL-17F, and their heterodimers IL-17A/F have inflammatory
effect with different strength; IL-17B, IL-17C, IL-17D are proin-
flammatory cytokines with unknown role. The IL-17E cytokine,
also named IL-25, is involved in Th2 cells response.2
Production of IL-17 is mainly operated by T helper type 17
(Th17), CD8+ T cells, cd T cells, invariant natural killer T cells
(iNKT), natural killer (NK) cells, natural Th17 cells, and lym-
phoid tissue inducer (LTi) cells.1
IL-17 exerts many physiological functions including: neu-
trophil recruitment, Th2 stimulation to provide an effective
response against extracellular organisms, macrophage produc-
tion of IL-1b and TNF-a, and inflammatory mediator matrix met-
alloproteinases (MMPs) induction.1
Despite of the important role of IL-17 cytokine in regulating
adaptive and innate immune systems,3 its overproduction could
be involved in several diseases.4
In recent years, different studies have tried to associate the
IL-17 pathway to an increasing number of inflammatory dis-
eases, such as asthma, chronic obstructive pulmonary disease
(COPD), lupus, polymyalgia rheumatica, giant cell arteritis,
Behcet disease, dry-eye syndrome, Sj€ogren’s syndrome, Crohn’s
disease, and multiple sclerosis. However, the role of IL-17 is still
unclear.4 Th17 cells and IL-17 have also been identified to be
implicated in the pathogenesis of several human autoimmune
diseases, such as rheumatoid arthritis, multiple sclerosis, inflam-
matory bowel disease, systemic sclerosis, primary Sjogren’s syn-
drome, alopecia areata, and vitiligo.5 Furthermore, a recent
study reported a correlation between the serum levels of IL-17
and activity of the disease in selected autoimmune bullous skin
diseases, such as dermatitis herpetiformis (DH), bullous pem-
phigoid (BP), and pemphigus vulgaris (PV).6
Even though the role of IL-17 in inflammatory and autoim-
mune diseases has been reported extensively, its role in tumors
is still controversial.7
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In an attempt to contribute to the description of the relationship
between IL-17 pathways and the most frequent dermatological
diseases, we report the state of the art about the role of IL-17 in
psoriasis, atopic dermatitis, acne, hidradenitis suppurativa, viti-
ligo, alopecia areata, nonmelanoma skin cancer, and melanoma.
IL-17 and Inflammatory Skin Diseases
Psoriasis
Recent evidences highlighted the importance of IL-17A in the
pathogenesis of psoriasis and psoriatic arthritis. IL-17A upregu-
lates the expression of inflammation-related genes in ker-
atinocytes and fibroblasts, resulting in the production of
inflammatory cytokines, chemokines, and other mediators and
the consequent clinical features.8
Linag et al. support the emergent role of IL-17 in psoriasis
pathogenesis, proving its effects on keratinocyte cultures to
increase the expression of antimicrobial peptides (e.g. S100) and
chemokines (e.g. CCL20) that activate and recruit neutrophils
and T cells.9 Recent data reported a serum increase of IL-17 in
psoriatic patients.10 The IL-17 binding to its receptor (IL-17R)
expressed by keratinocytes promotes the aberrant differentiation
and proliferation of keratinocytes, the expression of chemokines
(CXCL1, CXCL2, and CCL20) which enhance recruitment of
Th17 and dendritic cells to the skin, the expression of antimicro-
bial peptides, and reduces the expression of cell adhesion mole-
cules, resulting in disruption of skin barrier function.11
Zhang et al. in a recent work on a pediatric population
reported a significantly higher frequency of Th17 and its cytoki-
nes in psoriatic patients’ blood compared with healthy controls,
pointing out a significantly positively relation between the
increase of Th17 blood frequency and patient PASI.12 Likewise,
Sofen et al. and Chiricozzi et al. reported a significant correla-
tion between IL-17 serum levels and disease severity, while Yil-
maz et al. found an increase in IL-17 in serum of patients with
PASI > 10 more than patients with PASI < 10.13–15 Different
authors have studied the correlation between serum levels of
IL-17 or its tissue expression and the clinical subtype of psoria-
sis or disease state.16,17 Recently, the central role of IL-17 in
systemic inflammation and cardiovascular comorbidity in psoria-
sis patients has also been highlighted.18–20
Finally, the evidence of the role of IL-17 in the pathogenesis
of psoriasis has been supported by the proven efficacy of the
treatment with anti-IL-17 in psoriatic patients.8,21,22
In particular, the biological agent brodalumab proved its effi-
cacy and safety in generalized pustular psoriasis.23
Atopic dermatitis
The central role of cytokines in the pathogenesis of atopic der-
matitis (AD) has been widely highlighted. Interleukin-4 and inter-
leukin-13 are major causes of inflammation and itch in
patients.24 Recently, the role of Th17 cells and IL-17 in the
pathogenesis of AD has been investigated. Th17 cells play a
potential role in the immune activation, including attraction of
neutrophils.25 An increase in IL-17A, IL-17E, IL-17F, and IL-23
serum concentrations has been demonstrated in children suffer-
ing from AD, which correlated with disease severity.26 Elevated
IL-17A and IL-17E levels were found in the papillary dermis of
AD lesions, especially in the acute phase.27 In AD mouse mod-
els, IL-17E is upregulated inducing the expression of endothe-
lin-1, which is an important factor in developing pruritus.28 IL-
17E may be responsible for skewing the immune response to a
Th2 dominance and decreases filaggrin production in ker-
atinocytes, resulting in disorders of keratinization and an
impaired skin barrier function/homeostasis.29 Considering the
role of IL-17 in the pathogenesis of DA, it is reasonable to spec-
ulate a possible effectiveness of anti-IL-17 in the treatment of
AD. As anti-IL-17A therapy in psoriasis increases the risk of
neutropenia and skin and oral candida infections, it seems rea-
sonable to be cautious, as AD patients are more prone to skin
and mucosal infections than patients suffering from psoriasis.30
Acne
The evidence of the presence of inflammatory factors in the
very earliest stages of acne lesion prior to hyperproliferation of
the follicular epithelium raises questions on the primary key role
of inflammation in the pathogenesis of acne.31
Recently, the role of Th17 in acne lesions is under investiga-
tion. Examination of inflammatory changes in early acne lesions
in two separate patient cohorts revealed a significant overex-
pression of cytokines involved in Th17 pathways.32 Agak et al.
confirmed these findings, demonstrating the ability of P. acnes
in inducing both Th17 and Th1 responses as measured, respec-
tively, by IL-17 and INF-ɤ in human peripheral blood mononu-
clear cells (PBMCs) in vitro, as well as the expression of Th17
differentiation markers including RORa, RORc, and IL-17RA
and IL-17RC.33 Moreover, at immunohistochemical examination,
IL-17 expressing cells were detectable only in the epidermis of
acne patients. CD4+CD25+Foxp3+ regulatory T-cells (T-regs), a
population linked to Th17 cells, are significantly increased in
acne lesions. The differentiation of both Th17 cells and T-regs
depends on the cytokines present in the environment.34
In a recent study, Kistowska et al. suggested that acne may
be a Th17-mediated disease because P. acnes is a potent indu-
cer of IL-17 and IFN-gamma from CD4+ T cells and that IL-17+
cells were present in perifollicular infiltrates in biopsy samples
of inflammatory acne lesions.35
Another study has highlighted some therapeutic implications of
the Th17 pathway in patients with acne.36 Some drugs, such as
dihydroxyvitamin D3, retinoids, vitamin A, and zinc, could have a
successful role in the treatment of acne because of their inhibition
of inflammatory Th17 and promotion of T-reg responses.37
Hidradenitis suppurativa
Recent research focused on the inflammatory mechanisms
involved in HS, suggesting a key role for immune dysregulation
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in its pathogenesis. Schlapbach et al. investigating the expres-
sion and cellular source of IL-12, IL-23, and IL-17 in lesional
skin reported that IL-17 and IL-23, which play a central role in
the regulation of Th17 cells, were highly expressed.38 Van der
Zee et al., comparing the cytokine levels in lesional HS skin
biopsies after 24 hours of culture with the levels in healthy skin,
showed that levels of IL-1b, TNF-a IL-6, and IL-17 were ele-
vated in HS lesions.39 Similarly, Kelly et al. reported that the
mRNA expression of IL-17A, IL-1b, TNFa, and IL-10 is
enhanced in lesional skin. In addition, they showed a significant
enhancement of IL-17A in uninvolved skin of patients with HS
10 cm away from any lesional activity.40 Based on these data,
the abnormal expression of IL-17 and its associated cytokine
detected in lesional skin and uninvolved skin supported the
hypothetical role of Th17 in lesion development. Likewise, Lima
et al. demonstrated that the Th17 cells and neutrophils are sig-
nificantly increased in lesional and perilesional skin with homo-
geneous distribution in the perifollicular region.41 The evidences
supporting the role of IL-17 in the pathogenesis of HS provided
a rationale for treating hidradenitis with anti-IL-17 antibodies,
especially in case of HS refractory to local and systemic antibi-
otic therapy as well as other biological drugs.42
IL-17 and Autoimmune Skin Diseases
Vitiligo
Several human studies have investigated the roles that Th17
cells play in vitiligo, demonstrating an increased frequency of
circulating Th17 cells and elevated serum levels of IL-17 that
positively correlates with disease duration, extent, and severity
of disease.43
In a recent study, Kotobuki et al. confirmed the presence of
Th17 cell infiltration in vitiligo skin and speculated that Th17
cells do not exert a direct effect on the melanocytes but by pro-
ducing cytokines.44 Therefore, the presence of a cytokine net-
work and the secretion of IL-17A from Th17 cells may represent
a new mechanism underlying the pathogenesis of vitiligo.
Assessing the role of IL-17 in the pathogenesis of vitiligo,
Bassiouny et al. demonstrated elevated IL-17 levels in lesional
skin, while Basak et al. showed a positive correlation between
serum IL-17 levels and the extent of the depigmentation area in
vitiligo.45,46
Evaluating the frequencies of peripheral blood Th17 cells and
serum levels of IL-17A and Th17 cell-related cytokines in 45
patients with NSV, Zhou et al. showed increased circulating
Th17 cells as well as elevated serum IL-17A, TGF-b1, and IL-
21 levels in NSV patients, suggesting their potential involvement
in the development and progression of NSV.47 These data sup-
ported the evidence that Th1 and Th17 played an important role
in cellular immunity in the progression of vitiligo.
Further clinical studies are needed to confirm this correlation
and to determine the implications of directly targeting the IL-17
pathway in order to treat vitiligo.
Alopecia areata
Recent evidences highlighted the role of both Th17 cells and T
regulatory (Treg) cells in the pathogenesis of alopecia areata
(AA).48,49 Loh et al. carried out a study in order to determine
whether AA is associated with alterations in lesional and serum
Th17 and Treg cytokines. Studying scalp biopsies and serum
samples from AA patients, they found out that lesional IL-17, IL-
22, and serum IL-1, IL-17, TNF-a, and TGF-b were significantly
higher in AA patients than in controls. Moreover, they demon-
strated that there were positive correlations between lesional
and serum IL-17 and disease severity.48
A similar result has been demonstrated recently in another
study which found higher serum IL-17 level in patients with AA
than in control subjects. In particular, El-Morsy et al. revealed
significantly higher serum IL-17A levels in patients aged
≤30 years compared with those aged >30 years. This significant
negative correlation between patient age and serum IL-17A was
not detected in the control group.49 With regard to the associa-
tion among IL-17A levels and gender, age, disease duration,
subtype, or number of patches, Atwa et al. found that the con-
centrations of IL-17 are associated with disease severity and
are different according to the clinical phenotype being lowest in
patients with only one patch of hair loss and highest in alopecia
universalis/totalis.50
Tanemura et al., performing immunofluorescent study of
alopecia lesions, detected a significant infiltration of CD4+ IL-
17A+ Th17 cells in the dermis, particularly around hair follicles,
suggesting the involvement of Th17 cells in the pathogenesis of
AA.51
These results provide evidence on a functional role of TH17
and IL-17 in the pathogenesis of AA and highlighted the poten-
tial therapeutic role by targeting Th17 cytokines for the treat-
ment of AA.
IL-17 and Oncological Skin Diseases
NMSC
Besides other features, Th17 cells are characterized by pro- or
antitumorigenic properties depending on the stimuli of the
microenviroment.7 Some reports showed that Th17 cells eradi-
cate tumors, while others revealed that they promote the initia-
tion and early growth of tumors.52 The microenvironment can
exert inhibitory effects on malignant cells, but tumors can cir-
cumvent these inhibitory signals and use the surrounding cells
for their own survival, causing growth, invasion, and metastasis.
The generation of Th17 cells with different phenotypes in
response to tumor microenvironment would explain the conflict-
ing observations.7
One evident role of Th17 cells in tumor progression is their
contribution to local inflammation. Cytokines produced by inflam-
matory Th17 cells stimulate inflammation-dependent tumor
growth by promoting angiogenesis and by suppressing antitumor
immunity.53 Particularly regarding NMSC, Nardinocchi et al.
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investigated the role of IL-17 and IL-22 in the growth and inva-
siveness of human skin basal-cell carcinoma (BCC) and squa-
mous-cell carcinoma (SCC). They showed that both tumor types
are infiltrated with a high number of IL-17+ and IL-22+ T lympho-
cytes. In vitro studies demonstrated that IL-17 increased the pro-
liferation and migration of the BCC- and SCC-cell lines M77015
and CAL27. This study, demonstrating a pro tumorigenic role of
IL-17 in human SCCs and BCCs, suggested treatment with anti-
IL-17 antibodies as a therapeutic approach in selected cases.54
In addition, an Italian group investigated changes of expres-
sion of IFN-c, IL-17, IL-23, and IL-22 cytokines in BCC and their
modulation during imiquimod (IMQ) treatment or photodynamic
therapy (PDT). Increased levels of IFN-c, IL-17, IL-23, and IL-
22 were found in BCCs compared to normal skin, and their
expression results correlated with the severity of the inflamma-
tory infiltrate. Moreover, IL-17 was increased in nodular forms.
Finally, they highlighted an increase of IFN-c, IL-23, and IL-22,
IL-17 because of early inflammatory response induced by IMQ
and PDT treatment.55
These findings confirm the role of Th17 and related cytokines
in NMSC pathogenesis and in the inflammatory response during
therapies.
Melanoma
The role of Th17 and IL-17 in melanoma is complex, as it has
been reported in NMSC. Effects of Th17 and IL-17 in murine
models of cancer has been investigated, showing that Th17
cells activate endogenous cytotoxic CD8+ T cells and eradicate
melanoma in mice.56 Muranski et al. reported that Th17-polar-
ized cells better mediated destruction of advanced B16 mela-
noma, and their therapeutic effect was critically dependent on
interferon (IFN) production.57 In murine B16 melanoma, it has
been shown that the tumor-promoting role of IL-17 has a direct
effect on tumor cells through an IL-6-Stat3 signaling pathway.58
Recently, Jun Li et al. demonstrated that IL-7/IL-7R-Stat3-IL-
17 pathway promotes melanoma growth, and its inhibition may
contribute to tumor growth in murine models of melanoma.59
Based on these evidences, Ganzetti et al. have speculated
that this model could be reproducible in human cutaneous mela-
noma. They studied the expression of interleukin-17 (IL-17), IL-
23, and p73 in 35 malignant melanomas comparing them with
benign melanocytic nevi and Spitz nevi. Their results showed a
greater IL-17 and IL-23 immunohistochemistry expression in the
melanoma group than in ordinary benign nevi.60 These results
could suggest a possible IL-17, IL-23, and p73 involvement in
cutaneous melanomas with a hypothetical impact on melanoma
invasiveness.
It has been hypothesized that IL-17 may stimulate cancer
cells to produce some angiogenic factors (VEGF), thereby
enhancing tumor angiogenesis.58 These results could suggest a
direct impact on the biological behavior of tumor cells in the
local microenvironment and could explain the increased expres-
sion of VEGF and angiogenesis in invasive melanomas.
In patients with advanced inoperable melanoma, a better
understanding of the regulation of cytokine and cellular immune
activity in response to melanoma may be important in order to
predict therapeutic response to immunotherapy, including treat-
ment with ipilimumab. A recent study showed that in patients
with regionally advanced melanoma enrolled in a trial of neoad-
juvant therapy with ipilimumab at 10 mg/kg, baseline IL-17 level
was significantly associated with the risk of subsequent devel-
opment of severe immune-mediated diarrhea/colitis.61 Further
investigation and confirmation in larger trials is necessary in
order to confirm these findings.
Conclusion
We reported a global up-to-date overview about the role of IL-
17 in inflammatory, autoimmune, and oncological skin dis-
eases. The literature data suggest that this cytokine has been
implicated in these diseases with different pathways. It could
be hypothesized that IL-17 might represent a link between dif-
ferent diseases underlying a common pathogenic basis where
inflammation could be considered the distinctive benchmark
and this cytokine as a marker. Further clinical studies are
needed to confirm this correlation and to determine its implica-
tions for the development of new therapeutic approaches as
well as the monitoring of disease activity and therapeutic
response.
Questions (answers provided after
references)
True/False
1 All the family members of IL-17 family have an inflammatory
effect.
2 The pathogenetic mechanisms triggered by the binding of IL-
17 with its receptor in patients with psoriasis result in disrup-
tion of skin barrier function.
3 There is no evidence about the efficacy of treatment with
anti-IL-17 in psoriatic patients.
4 Psoriatic patients are more prone to skin and mucosal infec-
tions than patients suffering from atopic dermatitis.
5 Some drugs, such as dihydroxyvitamin D3, retinoids, vitamin
A, and zinc, have a successful role in the treatment of acne
because of their inhibition of inflammatory Th17.
6 In the case of HS refractory to antibiotic therapy or other bio-
logical drugs, there is evidence that supports the role of IL-17
in the pathogenesis of HS and provides a rationale for treat-
ing hidradenitis with anti-IL-17.
7 In a recent study, is it confirmed that Th17 cells exert a direct
effect on melanocytes.
8 Is it demonstrated that the concentrations of IL-17 are associ-
ated with disease severity and are different according to the
clinical phenotype.
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9 Th17 cells are characterized by pro- or anti-tumorigenic prop-
erties depending on the stimuli of the microenvironment.
10 Better understanding of the regulation of IL-17 and cellular
immune activity in response to melanoma to predict thera-
peutic response to immunotherapy could be an advantage
for patients with advanced inoperable melanoma.
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